Author/Creator: Giuliano, Claudio - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Giuliano, Claudio

1. Challenges in the Development of Intravenous Neurokinin‐1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose‐Finding, Phase 1 Study of Intravenous Fosnetupitant. Issue 12 (20th October 2022)

Authors:: Tyler, Timothy; Schultz, Armin; Venturini, Alessio; Giuliano, Claudio; Bernareggi, Alberto; Spezia, Riccardo; Voisin, Daniel; Stella, Valentino
Journal:: Clinical pharmacology in drug development
Issue:: Volume 11:Issue 12(2022)
Page Start:: 1405
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. Ghrelin receptor inverse agonists as a novel therapeutic approach against obesity‐related metabolic disease. Issue 12 (13th July 2017)

Authors:: Abegg, Kathrin; Bernasconi, Lara; Hutter, Melanie; Whiting, Lynda; Pietra, Claudio; Giuliano, Claudio; Lutz, Thomas A.; Riediger, Thomas
Journal:: Diabetes, obesity & metabolism
Issue:: Volume 19:Issue 12(2017)
Page Start:: 1740
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. Netupitant PET imaging and ADME studies in humans. (8th November 2013)

Authors:: Spinelli, Tulla; Calcagnile, Selma; Giuliano, Claudio; Rossi, Giorgia; Lanzarotti, Corinna; Mair, Stuart; Stevens, Lloyd; Nisbet, Ian
Journal:: Journal of clinical pharmacology
Issue:: Volume 54:Number 1(2014:Jan.)
Page Start:: 97
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. Relevance of Biochemical Deep Phenotyping for a Personalised Approach to Parkinson's Disease. (10th February 2023)

Authors:: Giuliano, Claudio; Cerri, Silvia; Cesaroni, Valentina; Blandini, Fabio
Journal:: Neuroscience
Issue:: Volume 511(2023)
Page Start:: 100
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

5. The brain‐penetrating, orally bioavailable, ghrelin receptor agonist HM01 ameliorates motion‐induced emesis in Suncus murinus (house musk shrew). (3rd February 2020)

Authors:: Tu, Longlong; Lu, Zengbing; Ngan, Man P.; Lam, Francis F.Y.; Giuliano, Claudio; Lovati, Emanuela; Pietra, Claudio; Rudd, John A.
Journal:: British journal of pharmacology
Issue:: Volume 177:Number 7(2020)
Page Start:: 1635
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗